Failure of Pentoxifylline or Cilostazol to Improve Blood and Plasma Viscosity, Fibrinogen, and Erythrocyte Deformability in Claudication
Peripheral artery disease is associated with altered blood rheologic properties, including increased viscosity and decreased red blood cell (RBC) deformability. Pentoxifylline and cilostazol are available therapies for intermittent claudication. Improvement of blood viscosity and erythrocyte deforma...
Gespeichert in:
| Veröffentlicht in: | Angiology 2002-09, Vol.53 (5), p.509-520 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 520 |
|---|---|
| container_issue | 5 |
| container_start_page | 509 |
| container_title | Angiology |
| container_volume | 53 |
| creator | Dawson, David L. Qintian Zheng Worthy, Sue A. Charles, Brandie Bradley, Donald V. |
| description | Peripheral artery disease is associated with altered blood rheologic properties, including increased viscosity and decreased red blood cell (RBC) deformability. Pentoxifylline and cilostazol are available therapies for intermittent claudication. Improvement of blood viscosity and erythrocyte deformability have been cited as potential mechanisms of action for pentox ifylline. Cilostazol is a new drug with antiplatelet and vasodilating activity, but the mechanism by which it promotes an improvement in walking is not known. This study was performed to evaluate and compare the hemorheologic effects of pentoxifylline and cilostazol on viscosity, fibrinogen levels, and erythrocyte deformability when administered to adults with moderate to severe claudication. A double-blind, controlled study was conducted and included 59 patients (46 male, 13 female; mean age 65 yr) randomized to pentoxifylline 400 mg orally thrice daily (n=20), cilostazol 100 mg orally twice daily (n=19), or placebo (n=20); all subjects were observed for 24 weeks. Walking ability was assessed before, during, and at the conclusion of treatment by standard constant speed, variable grade treadmill testing. Erythrocyte deforma bility was measured by passage of washed RBCs, 10% hematocrit in phosphate buffered saline (PBS), through a polycarbonate membrane with 4.7 to 5.0 μm pores. Whole blood and plasma viscosity were measured using a cone/plate viscometer at variable shear rates (from 4.5 to 450 sec -1). Erythrocyte sedimentation rate was measured by a modified Westergren technique. Fibrinogen was assayed by a commercial reference laboratory. Plasma viscosities did not change significantly in any treatment group. Within-group comparisons demonstrated a significant (p |
| doi_str_mv | 10.1177/000331970205300503 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_72155236</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A92544158</galeid><sage_id>10.1177_000331970205300503</sage_id><sourcerecordid>A92544158</sourcerecordid><originalsourceid>FETCH-LOGICAL-c471t-d22979615aacaf8f34e7a0d3f147cd1f71b6f1f956fca01d4f2fc4e95d390c983</originalsourceid><addsrcrecordid>eNp90k9vFCEUAPCJ0di1-gU8GGKipx3Ln2FYjnXb1SZN7EG9Tt4ysNIwUIExTj-BH1vG3WQTbQwHAvk9eO9BVb0k-B0hQpxhjBkjUmCKOcOYY_aoWhDZ4Jpw0TyuFjOoZ3FSPUvptiw5we3T6oRQ1vIVF4vq1wasG6NGwaAb7XP4ac3knPVlJ6K1dSFluA8O5YCuhrsYfmj03oXQI_A9unGQBkBfbVIh2Twt0cZuo_Vhp_3yj7iMU_4Wg5qyRhfahDjA1rpCkfVo7WDsrYJsg39ePTHgkn5xmE-rL5vLz-uP9fWnD1fr8-taNYLkuqdUCtkSDqDArAxrtADcM0MaoXpiBNm2hhjJW6MAk74x1KhGS94ziZVcsdPq7f7cUsv3UafcDSV77Rx4HcbUCUo4L-0p8PVf8DaM0ZfcOkqbFaMEy4KWe7QDpzvrTcgRVKleR3DBa2PL9rmkvGkIny-vH-Bl9Hqw6iFP917FkFLUpruLdoA4dQR38x_o_v0DJejVIfFxO-j-GHJ49ALeHAAkBc5E8Mqmo2Ole7Kd3dneJdjpY_X_ufo3bovHHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>224832109</pqid></control><display><type>article</type><title>Failure of Pentoxifylline or Cilostazol to Improve Blood and Plasma Viscosity, Fibrinogen, and Erythrocyte Deformability in Claudication</title><source>MEDLINE</source><source>SAGE Complete A-Z List</source><creator>Dawson, David L. ; Qintian Zheng ; Worthy, Sue A. ; Charles, Brandie ; Bradley, Donald V.</creator><creatorcontrib>Dawson, David L. ; Qintian Zheng ; Worthy, Sue A. ; Charles, Brandie ; Bradley, Donald V.</creatorcontrib><description>Peripheral artery disease is associated with altered blood rheologic properties, including increased viscosity and decreased red blood cell (RBC) deformability. Pentoxifylline and cilostazol are available therapies for intermittent claudication. Improvement of blood viscosity and erythrocyte deformability have been cited as potential mechanisms of action for pentox ifylline. Cilostazol is a new drug with antiplatelet and vasodilating activity, but the mechanism by which it promotes an improvement in walking is not known. This study was performed to evaluate and compare the hemorheologic effects of pentoxifylline and cilostazol on viscosity, fibrinogen levels, and erythrocyte deformability when administered to adults with moderate to severe claudication. A double-blind, controlled study was conducted and included 59 patients (46 male, 13 female; mean age 65 yr) randomized to pentoxifylline 400 mg orally thrice daily (n=20), cilostazol 100 mg orally twice daily (n=19), or placebo (n=20); all subjects were observed for 24 weeks. Walking ability was assessed before, during, and at the conclusion of treatment by standard constant speed, variable grade treadmill testing. Erythrocyte deforma bility was measured by passage of washed RBCs, 10% hematocrit in phosphate buffered saline (PBS), through a polycarbonate membrane with 4.7 to 5.0 μm pores. Whole blood and plasma viscosity were measured using a cone/plate viscometer at variable shear rates (from 4.5 to 450 sec -1). Erythrocyte sedimentation rate was measured by a modified Westergren technique. Fibrinogen was assayed by a commercial reference laboratory. Plasma viscosities did not change significantly in any treatment group. Within-group comparisons demonstrated a significant (p<0.01) drop in whole blood viscosity (week 24 compared with week 0) for cilostazol-treated subjects (at shear rates of 45, 90, 225, and 450 sec-1), but these changes were not significantly different from those in the placebo group. There were no significant changes in whole blood viscosity for subjects treated with pentoxifylline or placebo. There were no significant changes in erythrocyte deformability, fibrinogen, or erythrocyte sedimen tation rate. A trend toward improved walking distances was noted for both pentoxifylline and cilostazol in comparison with placebo. This trend was not correlated with changes in any underlying rheologic parameter. Ex vivo rheologic characteristics of blood from patients with</description><identifier>ISSN: 0003-3197</identifier><identifier>EISSN: 1940-1574</identifier><identifier>DOI: 10.1177/000331970205300503</identifier><identifier>PMID: 12365857</identifier><identifier>CODEN: ANGIAB</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Adult ; Aged ; Analysis of Variance ; Biological and medical sciences ; Blood Viscosity - drug effects ; Cardiovascular system ; Data Interpretation, Statistical ; Double-Blind Method ; Drug therapy ; Erythrocyte Deformability - drug effects ; Evaluation ; Female ; Fibrinogen - drug effects ; Humans ; Intermittent claudication ; Intermittent Claudication - blood ; Intermittent Claudication - drug therapy ; Male ; Medical sciences ; Middle Aged ; Models, Biological ; Pentoxifylline ; Pentoxifylline - pharmacology ; Pentoxifylline - therapeutic use ; Peripheral vascular diseases ; Pharmacology. Drug treatments ; Placebos ; Platelet Aggregation Inhibitors - pharmacology ; Platelet Aggregation Inhibitors - therapeutic use ; Prospective Studies ; Tetrazoles - pharmacology ; Tetrazoles - therapeutic use ; Time Factors ; Vasodilator Agents - pharmacology ; Vasodilator Agents - therapeutic use ; Vasodilator agents. Cerebral vasodilators ; Walking</subject><ispartof>Angiology, 2002-09, Vol.53 (5), p.509-520</ispartof><rights>2002 INIST-CNRS</rights><rights>COPYRIGHT 2002 Sage Publications, Inc.</rights><rights>Copyright Westminster Publications, Inc. Sep/Oct 2002</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c471t-d22979615aacaf8f34e7a0d3f147cd1f71b6f1f956fca01d4f2fc4e95d390c983</citedby><cites>FETCH-LOGICAL-c471t-d22979615aacaf8f34e7a0d3f147cd1f71b6f1f956fca01d4f2fc4e95d390c983</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/000331970205300503$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/000331970205300503$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,777,781,21800,27905,27906,43602,43603</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=13956967$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/12365857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Dawson, David L.</creatorcontrib><creatorcontrib>Qintian Zheng</creatorcontrib><creatorcontrib>Worthy, Sue A.</creatorcontrib><creatorcontrib>Charles, Brandie</creatorcontrib><creatorcontrib>Bradley, Donald V.</creatorcontrib><title>Failure of Pentoxifylline or Cilostazol to Improve Blood and Plasma Viscosity, Fibrinogen, and Erythrocyte Deformability in Claudication</title><title>Angiology</title><addtitle>Angiology</addtitle><description>Peripheral artery disease is associated with altered blood rheologic properties, including increased viscosity and decreased red blood cell (RBC) deformability. Pentoxifylline and cilostazol are available therapies for intermittent claudication. Improvement of blood viscosity and erythrocyte deformability have been cited as potential mechanisms of action for pentox ifylline. Cilostazol is a new drug with antiplatelet and vasodilating activity, but the mechanism by which it promotes an improvement in walking is not known. This study was performed to evaluate and compare the hemorheologic effects of pentoxifylline and cilostazol on viscosity, fibrinogen levels, and erythrocyte deformability when administered to adults with moderate to severe claudication. A double-blind, controlled study was conducted and included 59 patients (46 male, 13 female; mean age 65 yr) randomized to pentoxifylline 400 mg orally thrice daily (n=20), cilostazol 100 mg orally twice daily (n=19), or placebo (n=20); all subjects were observed for 24 weeks. Walking ability was assessed before, during, and at the conclusion of treatment by standard constant speed, variable grade treadmill testing. Erythrocyte deforma bility was measured by passage of washed RBCs, 10% hematocrit in phosphate buffered saline (PBS), through a polycarbonate membrane with 4.7 to 5.0 μm pores. Whole blood and plasma viscosity were measured using a cone/plate viscometer at variable shear rates (from 4.5 to 450 sec -1). Erythrocyte sedimentation rate was measured by a modified Westergren technique. Fibrinogen was assayed by a commercial reference laboratory. Plasma viscosities did not change significantly in any treatment group. Within-group comparisons demonstrated a significant (p<0.01) drop in whole blood viscosity (week 24 compared with week 0) for cilostazol-treated subjects (at shear rates of 45, 90, 225, and 450 sec-1), but these changes were not significantly different from those in the placebo group. There were no significant changes in whole blood viscosity for subjects treated with pentoxifylline or placebo. There were no significant changes in erythrocyte deformability, fibrinogen, or erythrocyte sedimen tation rate. A trend toward improved walking distances was noted for both pentoxifylline and cilostazol in comparison with placebo. This trend was not correlated with changes in any underlying rheologic parameter. Ex vivo rheologic characteristics of blood from patients with</description><subject>Adult</subject><subject>Aged</subject><subject>Analysis of Variance</subject><subject>Biological and medical sciences</subject><subject>Blood Viscosity - drug effects</subject><subject>Cardiovascular system</subject><subject>Data Interpretation, Statistical</subject><subject>Double-Blind Method</subject><subject>Drug therapy</subject><subject>Erythrocyte Deformability - drug effects</subject><subject>Evaluation</subject><subject>Female</subject><subject>Fibrinogen - drug effects</subject><subject>Humans</subject><subject>Intermittent claudication</subject><subject>Intermittent Claudication - blood</subject><subject>Intermittent Claudication - drug therapy</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>Models, Biological</subject><subject>Pentoxifylline</subject><subject>Pentoxifylline - pharmacology</subject><subject>Pentoxifylline - therapeutic use</subject><subject>Peripheral vascular diseases</subject><subject>Pharmacology. Drug treatments</subject><subject>Placebos</subject><subject>Platelet Aggregation Inhibitors - pharmacology</subject><subject>Platelet Aggregation Inhibitors - therapeutic use</subject><subject>Prospective Studies</subject><subject>Tetrazoles - pharmacology</subject><subject>Tetrazoles - therapeutic use</subject><subject>Time Factors</subject><subject>Vasodilator Agents - pharmacology</subject><subject>Vasodilator Agents - therapeutic use</subject><subject>Vasodilator agents. Cerebral vasodilators</subject><subject>Walking</subject><issn>0003-3197</issn><issn>1940-1574</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2002</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNp90k9vFCEUAPCJ0di1-gU8GGKipx3Ln2FYjnXb1SZN7EG9Tt4ysNIwUIExTj-BH1vG3WQTbQwHAvk9eO9BVb0k-B0hQpxhjBkjUmCKOcOYY_aoWhDZ4Jpw0TyuFjOoZ3FSPUvptiw5we3T6oRQ1vIVF4vq1wasG6NGwaAb7XP4ac3knPVlJ6K1dSFluA8O5YCuhrsYfmj03oXQI_A9unGQBkBfbVIh2Twt0cZuo_Vhp_3yj7iMU_4Wg5qyRhfahDjA1rpCkfVo7WDsrYJsg39ePTHgkn5xmE-rL5vLz-uP9fWnD1fr8-taNYLkuqdUCtkSDqDArAxrtADcM0MaoXpiBNm2hhjJW6MAk74x1KhGS94ziZVcsdPq7f7cUsv3UafcDSV77Rx4HcbUCUo4L-0p8PVf8DaM0ZfcOkqbFaMEy4KWe7QDpzvrTcgRVKleR3DBa2PL9rmkvGkIny-vH-Bl9Hqw6iFP917FkFLUpruLdoA4dQR38x_o_v0DJejVIfFxO-j-GHJ49ALeHAAkBc5E8Mqmo2Ole7Kd3dneJdjpY_X_ufo3bovHHg</recordid><startdate>20020901</startdate><enddate>20020901</enddate><creator>Dawson, David L.</creator><creator>Qintian Zheng</creator><creator>Worthy, Sue A.</creator><creator>Charles, Brandie</creator><creator>Bradley, Donald V.</creator><general>SAGE Publications</general><general>Westminster</general><general>Sage Publications, Inc</general><general>SAGE PUBLICATIONS, INC</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20020901</creationdate><title>Failure of Pentoxifylline or Cilostazol to Improve Blood and Plasma Viscosity, Fibrinogen, and Erythrocyte Deformability in Claudication</title><author>Dawson, David L. ; Qintian Zheng ; Worthy, Sue A. ; Charles, Brandie ; Bradley, Donald V.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c471t-d22979615aacaf8f34e7a0d3f147cd1f71b6f1f956fca01d4f2fc4e95d390c983</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2002</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Analysis of Variance</topic><topic>Biological and medical sciences</topic><topic>Blood Viscosity - drug effects</topic><topic>Cardiovascular system</topic><topic>Data Interpretation, Statistical</topic><topic>Double-Blind Method</topic><topic>Drug therapy</topic><topic>Erythrocyte Deformability - drug effects</topic><topic>Evaluation</topic><topic>Female</topic><topic>Fibrinogen - drug effects</topic><topic>Humans</topic><topic>Intermittent claudication</topic><topic>Intermittent Claudication - blood</topic><topic>Intermittent Claudication - drug therapy</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>Models, Biological</topic><topic>Pentoxifylline</topic><topic>Pentoxifylline - pharmacology</topic><topic>Pentoxifylline - therapeutic use</topic><topic>Peripheral vascular diseases</topic><topic>Pharmacology. Drug treatments</topic><topic>Placebos</topic><topic>Platelet Aggregation Inhibitors - pharmacology</topic><topic>Platelet Aggregation Inhibitors - therapeutic use</topic><topic>Prospective Studies</topic><topic>Tetrazoles - pharmacology</topic><topic>Tetrazoles - therapeutic use</topic><topic>Time Factors</topic><topic>Vasodilator Agents - pharmacology</topic><topic>Vasodilator Agents - therapeutic use</topic><topic>Vasodilator agents. Cerebral vasodilators</topic><topic>Walking</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Dawson, David L.</creatorcontrib><creatorcontrib>Qintian Zheng</creatorcontrib><creatorcontrib>Worthy, Sue A.</creatorcontrib><creatorcontrib>Charles, Brandie</creatorcontrib><creatorcontrib>Bradley, Donald V.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Angiology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Dawson, David L.</au><au>Qintian Zheng</au><au>Worthy, Sue A.</au><au>Charles, Brandie</au><au>Bradley, Donald V.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Failure of Pentoxifylline or Cilostazol to Improve Blood and Plasma Viscosity, Fibrinogen, and Erythrocyte Deformability in Claudication</atitle><jtitle>Angiology</jtitle><addtitle>Angiology</addtitle><date>2002-09-01</date><risdate>2002</risdate><volume>53</volume><issue>5</issue><spage>509</spage><epage>520</epage><pages>509-520</pages><issn>0003-3197</issn><eissn>1940-1574</eissn><coden>ANGIAB</coden><abstract>Peripheral artery disease is associated with altered blood rheologic properties, including increased viscosity and decreased red blood cell (RBC) deformability. Pentoxifylline and cilostazol are available therapies for intermittent claudication. Improvement of blood viscosity and erythrocyte deformability have been cited as potential mechanisms of action for pentox ifylline. Cilostazol is a new drug with antiplatelet and vasodilating activity, but the mechanism by which it promotes an improvement in walking is not known. This study was performed to evaluate and compare the hemorheologic effects of pentoxifylline and cilostazol on viscosity, fibrinogen levels, and erythrocyte deformability when administered to adults with moderate to severe claudication. A double-blind, controlled study was conducted and included 59 patients (46 male, 13 female; mean age 65 yr) randomized to pentoxifylline 400 mg orally thrice daily (n=20), cilostazol 100 mg orally twice daily (n=19), or placebo (n=20); all subjects were observed for 24 weeks. Walking ability was assessed before, during, and at the conclusion of treatment by standard constant speed, variable grade treadmill testing. Erythrocyte deforma bility was measured by passage of washed RBCs, 10% hematocrit in phosphate buffered saline (PBS), through a polycarbonate membrane with 4.7 to 5.0 μm pores. Whole blood and plasma viscosity were measured using a cone/plate viscometer at variable shear rates (from 4.5 to 450 sec -1). Erythrocyte sedimentation rate was measured by a modified Westergren technique. Fibrinogen was assayed by a commercial reference laboratory. Plasma viscosities did not change significantly in any treatment group. Within-group comparisons demonstrated a significant (p<0.01) drop in whole blood viscosity (week 24 compared with week 0) for cilostazol-treated subjects (at shear rates of 45, 90, 225, and 450 sec-1), but these changes were not significantly different from those in the placebo group. There were no significant changes in whole blood viscosity for subjects treated with pentoxifylline or placebo. There were no significant changes in erythrocyte deformability, fibrinogen, or erythrocyte sedimen tation rate. A trend toward improved walking distances was noted for both pentoxifylline and cilostazol in comparison with placebo. This trend was not correlated with changes in any underlying rheologic parameter. Ex vivo rheologic characteristics of blood from patients with</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>12365857</pmid><doi>10.1177/000331970205300503</doi><tpages>12</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0003-3197 |
| ispartof | Angiology, 2002-09, Vol.53 (5), p.509-520 |
| issn | 0003-3197 1940-1574 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_72155236 |
| source | MEDLINE; SAGE Complete A-Z List |
| subjects | Adult Aged Analysis of Variance Biological and medical sciences Blood Viscosity - drug effects Cardiovascular system Data Interpretation, Statistical Double-Blind Method Drug therapy Erythrocyte Deformability - drug effects Evaluation Female Fibrinogen - drug effects Humans Intermittent claudication Intermittent Claudication - blood Intermittent Claudication - drug therapy Male Medical sciences Middle Aged Models, Biological Pentoxifylline Pentoxifylline - pharmacology Pentoxifylline - therapeutic use Peripheral vascular diseases Pharmacology. Drug treatments Placebos Platelet Aggregation Inhibitors - pharmacology Platelet Aggregation Inhibitors - therapeutic use Prospective Studies Tetrazoles - pharmacology Tetrazoles - therapeutic use Time Factors Vasodilator Agents - pharmacology Vasodilator Agents - therapeutic use Vasodilator agents. Cerebral vasodilators Walking |
| title | Failure of Pentoxifylline or Cilostazol to Improve Blood and Plasma Viscosity, Fibrinogen, and Erythrocyte Deformability in Claudication |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-20T15%3A18%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Failure%20of%20Pentoxifylline%20or%20Cilostazol%20to%20Improve%20Blood%20and%20Plasma%20Viscosity,%20Fibrinogen,%20and%20Erythrocyte%20Deformability%20in%20Claudication&rft.jtitle=Angiology&rft.au=Dawson,%20David%20L.&rft.date=2002-09-01&rft.volume=53&rft.issue=5&rft.spage=509&rft.epage=520&rft.pages=509-520&rft.issn=0003-3197&rft.eissn=1940-1574&rft.coden=ANGIAB&rft_id=info:doi/10.1177/000331970205300503&rft_dat=%3Cgale_proqu%3EA92544158%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=224832109&rft_id=info:pmid/12365857&rft_galeid=A92544158&rft_sage_id=10.1177_000331970205300503&rfr_iscdi=true |